POCT PCT in Outpatient LRTI

Status Completed

Clinical Trial Summary

Lower respiratory tract infections (LRTI) in patients with chronic lung diseases are a common acute reason to consult respiratory practitioners and often lead to inadequate prescription of antibiotics. The primary objective of the investigators study was to determine the diagnostic accuracy of point-of-care testing (POCT) for procalcitonin (PCT) in identifying pneumonia as a bacterial infection in outpatients with LRTI.

Clinical Trial Description

Lower respiratory tract infections (LRTI) are a common acute reason to consult general practitioners or lung specialists and most patients receive an antibiotic prescription. Despite the vast majority of LRTI are caused by viruses, the lack of clinical, radiological, and laboratory tests to safely rule out bacterial involvement in LRTI still drives antibiotic treatment today Procalcitonin (PCT) has been shown to be a useful biomarker for differentiating between viral and bacterial infections in the emergency department and is now available as a point-of-care testing (POCT). The primary objective of the investigators study was to determine the diagnostic accuracy of POCT PCT in identifying bacterial infection in outpatients with LRTI. All patients aged 18 years or older with signs and symptoms of an LRTI as the leading diagnosis of the respiratory physicians are eligible. The medical assistant measure PCT from venous or capillary whole blood using the portable commercially available BRAHMS PCT direct point-of-care test (Thermo-Fischer Scientific). The stepwise procedure involve pipetting 20µl of the sample into the test disc before loading this onto the analyzer and pressing run. This immunoassay provides a quantitative result in 20 minutes. In suspicion of pneumonia (positive auscultation finding or clinical noticed symptoms compatible with pneumonia) a chest x-ray will be done. Members of the study team conduct standardised phone interviews of all participants on day 28. ;

Study Design

Related Conditions & MeSH terms

Antimicrobial Stewardship
Community-acquired Pneumonia
Exacerbation Copd
Infections
Lower Respiratory Tract and Lung Infections

Clinical Trial Details

NCT number	NCT05380869
Study type	Interventional
Source	Hannover Medical School
Contact
Status	Completed
Phase	N/A
Start date	April 1, 2020
Completion date	April 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05722938` - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Phase 3
Terminated	`NCT04972318` - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia	N/A
Recruiting	`NCT06065618` - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting	`NCT03675178` - Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia	Phase 4
Not yet recruiting	`NCT04166110` - Antibiotic Therapy In Respiratory Tract Infections	N/A
Completed	`NCT02380352` - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections	Phase 4
Completed	`NCT01671280` - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)	N/A
Completed	`NCT02555852` - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	N/A
Recruiting	`NCT00752947` - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors	Phase 4
Completed	`NCT00140023` - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia	Phase 3
Recruiting	`NCT04089787` - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia	Phase 4
Completed	`NCT05356494` - Postural Drainage and PEP Technique in Community Acquired Pneumonia	N/A
Completed	`NCT05133752` - Oral Nemonoxacin in Treating Elderly Patients With CAP	Phase 4
Not yet recruiting	`NCT06291012` - Stopping Pneumonia Antibiotherapy Regimen Early	Phase 4
Recruiting	`NCT05002192` - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed	`NCT03452826` - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia	N/A
Terminated	`NCT04071041` - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.	Phase 3
Completed	`NCT03474991` - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP	Phase 3
Completed	`NCT01723644` - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia	N/A
Withdrawn	`NCT01662258` - Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

POCT PCT in Outpatient LRTI — POCT-PCT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms